Biohaven Therapeutics co-led Artizan Biosciences' latest round as part of an option and licensing agreement focusing on its inflammatory bowel disease drug candidates.

Artizan Biosciences, a US-based developer of treatments for inflammatory diseases spun out of Yale University, has collected $11m in a series A2 round co-led by biopharmaceutical company Biohaven Therapeutics.

Hatteras Venture Partners co-led the round, which also attracted spinout-focused investment firm Osage University Partners (OUP), Connecticut Innovations and Elm Street Ventures.

Artizan is working on therapies for inflammatory diseases linked to the intestinal microbiota. It will use the financing to advance the preclinical development of a lead programme aimed at…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn